Sugi Predict

Sugi Predict / Compounds / Aminobenzoic Acid

Aminobenzoic Acid

Aminobenzoic Acid

SCHEMBL2270342

Nc1ccc(C(=O)[O-])cc1.Nc1ccc(C(=O)[O-])cc1.[Zn+2]

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 16/20 0.54
▸ CA1 P00915 15/20 0.54
▸ MASP2 O00187 1/20 0.50
▸ PLAU P00749 1/20 0.50
▸ THPO P40225 1/20 0.50
▸ CA4 P22748 1/20 0.50
▸ APEX1 P27695 2/20 0.48
▸ F2 P00734 1/20 0.48
▸ PRSS1 P07477 1/20 0.48
▸ PRSS3 P35030 1/20 0.48
▸ MEN1 O00255 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aminobenzoic Acid SCHEMBL9316925 0.95 CA2 (0.54) CA2CA1CA4APEX1MEN1
Aminobenzoic Acid SCHEMBL3889308 0.95 CA2 (0.54) CA2CA1CA4APEX1MEN1
Aminobenzoic Acid SCHEMBL9317385 0.95 CA2 (0.54) CA2CA1CA4APEX1MEN1
Aminobenzoic Acid SCHEMBL269265 0.95 CA2 (0.54) CA2CA1CA4APEX1MEN1
Aminobenzoic Acid SCHEMBL10995557 0.95 CA2 (0.54) CA2CA1CA4APEX1MEN1
Aminobenzoic Acid SCHEMBL11049339 0.95 CA2 (0.54) CA2CA1CA4APEX1MEN1
Aminobenzoic Acid SCHEMBL9316920 0.95 CA2 (0.54) CA2CA1CA4APEX1MEN1
Aminobenzoic Acid SCHEMBL6028845 0.95 CA2 (0.54) CA2CA1CA4APEX1MEN1
Aminobenzoic Acid SCHEMBL233871 0.95 CA2 (0.54) CA2CA1CA4APEX1MEN1
Aminobenzoic Acid SCHEMBL19611844 0.95 CA2 (0.54) CA2CA1CA4APEX1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118599275-B Flame-retardant antibacterial PETG material, preparation method and application thereof in medical packaging 东莞市万塑成塑料有限公司 2025-02-11 — — CN claimed
CN-118599275-A Flame-retardant antibacterial PETG material, preparation method and application thereof in medical packaging 东莞市万塑成塑料有限公司 2024-09-06 — — CN claimed
EP-0210751-A2 Halogen-containing rubbers and their manufacture MARINE MAGNESIUM COMPANY (US) 1987-02-04 — — EP claimed
US-4632954-A WITH AMINOCARBOXY COMPOUNDS CALGON CORPORATION (US) 1986-12-30 — — US claimed
CN-118599275-B Flame-retardant antibacterial PETG material, preparation method and application thereof in medical packaging 东莞市万塑成塑料有限公司 2025-02-11 — — CN disclosed
CN-118599275-A Flame-retardant antibacterial PETG material, preparation method and application thereof in medical packaging 东莞市万塑成塑料有限公司 2024-09-06 — — CN disclosed
US-8003688-B2 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2011-08-23 — — US disclosed
US-7671086-B2 Pharmaceutical compositions comprising flavonoids and menthol IMMUPHARM A/S (DK) 2010-03-02 — — US disclosed
US-20090227670-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM A/S (DK) 2009-09-10 — — US disclosed
US-7585890-B2 Pharmaceutical compositions comprising flavonoids and menthol IMMUNPHARM A/S (DK) 2009-09-08 — — US disclosed
EP-2089422-A1 METHODS OF SEPARATING NUCLEIC ACIDS AND PROTEIN Natimmune A/S (DK) 2009-08-19 — — EP disclosed
WO-2008106979-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND XYLITOL IMMUPHARM A/S (DK) 2008-09-12 — — WO disclosed
US-20040053858-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2004-03-18 — — US disclosed
EP-1307189-A2 METHOD OF TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT Immupharm APS (DK) 2003-05-07 — — EP disclosed
WO-2002009699-A2 METHOD OF TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT IMMUPHARM APS (DK) 2002-02-07 — — WO disclosed
EP-0189760-B1 THERMOSENSITIVE RECORDING SHEET JUJO PAPER CO., LTD. (JP) 1989-07-19 — — EP disclosed
US-4721701-A Thermosensitive recording sheet JUJO PAPER CO., LTD. (JP) 1988-01-26 — — US disclosed
EP-0210751-A2 Halogen-containing rubbers and their manufacture MARINE MAGNESIUM COMPANY (US) 1987-02-04 — — EP disclosed
US-4632954-A WITH AMINOCARBOXY COMPOUNDS CALGON CORPORATION (US) 1986-12-30 — — US disclosed
EP-0189760-A1 Thermosensitive recording sheet JUJO PAPER CO., LTD. (JP) 1986-08-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053858-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract CMA1, CHIA, C1QBP CA2 72/4885CA1 1151/4885MASP2 25/4885
US-20090227670-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL CHIA, MAVS, C1QBP CA2 3093/4885CA1 4600/4885MASP2 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.